# HealthEquity, Inc. (HQY) Stock Analysis: Strong Buy Ratings and 36% Potential Upside Make It a Healthcare Gem

- Link: https://www.directorstalkinterviews.com/healthequity-inc-hqy-stock-analysis-strong-buy-ratings-and-36-potential-upside-make-it-a-healthcare-gem/4121214395
- Published: 2025-09-01T10:36:06+01:00
- Author: Madison Wilson

HealthEquity, Inc. (HQY) is a prominent player in the health information services
industry, offering technology-enabled platforms that are revolutionizing the way
consumers and employers manage health savings accounts and related benefits. With
a market capitalization of $7.72 billion, this U.S.-based company is making significant
waves in the healthcare sector.

Currently trading at $89.33, HealthEquity’s stock price has seen a modest change
of 0.01% recently. However, it is the broader picture that makes HQY a compelling
choice for investors. The stock’s 52-week range spans from $74.69 to $114.51, suggesting
that there is room for growth, especially when considering the bullish analyst sentiment.

Analysts have expressed strong confidence in HealthEquity, with 13 buy ratings and
only one hold rating, underscoring its potential as a solid investment. The consensus
target price ranges between $104.00 and $130.00, with an average target of $121.50.
This positions the stock for a potential upside of 36.01%.

One of the key financial metrics that investors should consider is the company’s
forward P/E ratio of 20.26. Although the trailing P/E ratio is not available, the
forward-looking P/E suggests that the market expects growth in the company’s earnings,
which aligns with its impressive revenue growth rate of 15.00%.

For those focused on cash flow, HealthEquity reports a robust free cash flow of 
$96 million, providing a strong foundation for reinvestment into the business or
potential strategic initiatives. Additionally, the company maintains a return on
equity of 5.77%, which, while not amongst the highest in the industry, indicates
a steady return on shareholders’ investments.

Despite the absence of a dividend yield, HealthEquity’s 0.00% payout ratio suggests
that all earnings are being reinvested into the company, signaling a focus on long-
term growth rather than immediate shareholder returns. This reinvestment strategy
is often appealing to growth-oriented investors who are more interested in capital
appreciation.

The technical indicators provide a nuanced view of the stock’s current momentum.
The 50-day and 200-day moving averages are $95.58 and $97.69, respectively, indicating
that the stock is currently trading below both averages. This might suggest a potential
buying opportunity for investors looking to capitalize on a rebound. Additionally,
the RSI (14) of 51.44 suggests a balanced market sentiment, neither overbought nor
oversold.

HealthEquity’s MACD of -1.92 and a signal line of -2.10 indicate a bearish trend,
yet these technical patterns often precede significant shifts, especially when aligned
with strong fundamental data and analyst support.

Given its strategic position in the health information services sector and strong
analyst endorsements, HealthEquity stands out as a compelling investment opportunity
for those seeking exposure to the healthcare industry. Investors should keep a close
eye on this stock, as the combination of growth potential and strong buy ratings
make it a notable contender for portfolio inclusion.

Share on:
